{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:30Z","timestamp":1790887770829,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["22HXFH006"],"award-info":[{"award-number":["22HXFH006"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["22HXFH006"],"award-info":[{"award-number":["22HXFH006"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["22HXFH006"],"award-info":[{"award-number":["22HXFH006"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["22HXFH006"],"award-info":[{"award-number":["22HXFH006"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s15010-025-02620-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:03:38Z","timestamp":1755086618000},"page":"2717-2726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of therapeutic exposure and pharmacokinetic variability of second-line anti-TB drugs in MDR-TB patients: a retrospective study"],"prefix":"10.1007","volume":"53","author":[{"given":"Chilie","family":"Quncuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Dan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"2620_CR1","unstructured":"Organization WH. Global Tuberculosis Report 2024 Geneva: World Health Organization; 2024 [Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"2620_CR2","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization \u00a9 World Health Organization 2022.; 2022."},{"issue":"8","key":"2620_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354.","journal-title":"Drugs"},{"key":"2620_CR4","doi-asserted-by":"publisher","first-page":"100444","DOI":"10.1016\/j.jctube.2024.100444","volume":"36","author":"NF Maranchick","year":"2024","unstructured":"Maranchick NF, Peloquin CA. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2024;36:100444.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"2","key":"2620_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","volume":"72","author":"MC Cholo","year":"2017","unstructured":"Cholo MC, Mothiba MT, Fourie B, Anderson R. Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents Clofazimine and bedaquiline. J Antimicrob Chemother. 2017;72(2):338\u201353.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2620_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1128\/AAC.00191-13","volume":"57","author":"EM Svensson","year":"2013","unstructured":"Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of Efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"2620_CR7","doi-asserted-by":"crossref","unstructured":"Rowe DJ, Owens DR, Nedeljkovic M, Stirling CJ, Cathie K, Parker SL, et al. editors. Improving tuberculosis treatment using mid-infrared spectroscopy for bedside therapeutic drug monitoring. Silicon Photonics XVIII; 2023: SPIE.","DOI":"10.1117\/12.2649135"},{"issue":"10","key":"2620_CR8","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93\u2013142.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2620_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/157488410791110797","volume":"5","author":"V Dartois","year":"2010","unstructured":"Dartois V, Barry CE. Clinical Pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol. 2010;5(2):96\u2013114.","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"2620_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12879-017-2226-y","volume":"17","author":"Y Alkabab","year":"2017","unstructured":"Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum Microbiological clearance in virginia, USA. BMC Infect Dis. 2017;17(1):125.","journal-title":"BMC Infect Dis"},{"key":"2620_CR11","doi-asserted-by":"crossref","unstructured":"Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB et al. Practices of therapeutic drug monitoring in tuberculosis: an international survey. Eur Respir J. 2022;59(4).","DOI":"10.1183\/13993003.02787-2021"},{"issue":"6","key":"2620_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","volume":"60","author":"MGG Sturkenboom","year":"2021","unstructured":"Sturkenboom MGG, M\u00e4rtson AG, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, et al. Population pharmacokinetics and bayesian dose adjustment to advance TDM of Anti-TB drugs. Clin Pharmacokinet. 2021;60(6):685\u2013710.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2620_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","volume":"17","author":"AG M\u00e4rtson","year":"2021","unstructured":"M\u00e4rtson AG, Burch G, Ghimire S, Alffenaar JC, Peloquin CA. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23\u201339.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2620_CR14","doi-asserted-by":"crossref","unstructured":"Davies Forsman L, Niward K, Kuhlin J, Zheng X, Zheng R, Ke R et al. Suboptimal Moxifloxacin and Levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. Eur Respir J. 2021;57(3).","DOI":"10.1183\/13993003.03463-2020"},{"issue":"13","key":"2620_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for Rifampin-Resistant tuberculosis. N Engl J Med. 2019;380(13):1201\u201313.","journal-title":"N Engl J Med"},{"key":"2620_CR16","doi-asserted-by":"crossref","unstructured":"Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6).","DOI":"10.1183\/13993003.01522-2019"},{"issue":"5","key":"2620_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.5588\/ijtld.13.0268","volume":"18","author":"WY Hung","year":"2014","unstructured":"Hung WY, Yu MC, Chiang YC, Chang JH, Chiang CY, Chang CC, et al. Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Int J Tuberc Lung Dis. 2014;18(5):601\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"2620_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.5588\/ijtld.17.0648","volume":"22","author":"H Zhu","year":"2018","unstructured":"Zhu H, Guo SC, Liu ZQ, Wang B, Fu L, Chu NH, et al. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in beijing, China. Int J Tuberc Lung Dis. 2018;22(8):931\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"2620_CR19","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/cid\/ciz942","volume":"70","author":"JC Alffenaar","year":"2020","unstructured":"Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70(8):1774\u201380.","journal-title":"Clin Infect Dis"},{"issue":"10226","key":"2620_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(20)30049-0","volume":"395","author":"HY Kim","year":"2020","unstructured":"Kim HY, Heysell SK, Mpagama S, Marais BJ, Alffenaar JW. Challenging the management of drug-resistant tuberculosis. Lancet. 2020;395(10226):783.","journal-title":"Lancet"},{"issue":"2","key":"2620_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1183\/13993003.01285-2015","volume":"47","author":"EP van der Burgt","year":"2016","unstructured":"van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, et al. End TB with precision treatment! Eur Respir J. 2016;47(2):680\u20132.","journal-title":"Eur Respir J"},{"issue":"1","key":"2620_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/cid\/ciw677","volume":"64","author":"JC Alffenaar","year":"2017","unstructured":"Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis. 2017;64(1):104\u20135.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2620_CR23","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020;75(11):3269\u201377.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2620_CR24","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RP van Heeswijk","year":"2014","unstructured":"van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69(9):2310\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2620_CR25","doi-asserted-by":"crossref","unstructured":"Alffenaar JC, Akkerman OW, Tiberi S, Sotgiu G, Migliori GB. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Eur Respir J. 2020;55(2).","DOI":"10.1183\/13993003.01908-2019"},{"issue":"2","key":"2620_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/AAC.45.2.382-392.2001","volume":"45","author":"Z Desta","year":"2001","unstructured":"Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent Inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45(2):382\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"2620_CR27","doi-asserted-by":"crossref","unstructured":"Eloy G, Lebeaux D, Launay M, Fernandez-Gerlinger MP, Billaud E, Douez E et al. Influence of renal function and age on the pharmacokinetics of Levofloxacin in patients with bone and joint infections. Antibiot (Basel). 2020;9(7).","DOI":"10.3390\/antibiotics9070401"},{"issue":"5","key":"2620_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1128\/AAC.42.5.1098","volume":"42","author":"SL Preston","year":"1998","unstructured":"Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42(5):1098\u2013104.","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"2620_CR29","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","volume":"342","author":"DS Pratt","year":"2000","unstructured":"Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266\u201371.","journal-title":"N Engl J Med"},{"key":"2620_CR30","doi-asserted-by":"crossref","unstructured":"Ahmad J, Dellinger A, Nicoletti P, Barnhart HX, Ghabril M, Fontana RJ et al. Clinical and HLA associations of fluoroquinolone induced liver injury: results from the Drug-Induced liver injury network. Am J Gastroenterol. 2025. Published online ahead of print","DOI":"10.14309\/ajg.0000000000003457"},{"key":"2620_CR31","doi-asserted-by":"crossref","unstructured":"Wu Z, Sun W, Wang C. Retrospective analysis of clinical features of liver injury induced by Levofloxacin. Expert Opin Drug Saf. 2025;1\u20137. Published online ahead of print","DOI":"10.1080\/14740338.2025.2494685"},{"issue":"2","key":"2620_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2215\/CJN.03960609","volume":"5","author":"C Aymanns","year":"2010","unstructured":"Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5(2):314\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2620_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-025-01494-4","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: A review. Clin Pharmacokinet. 2025;64(3):335\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2620_CR34","first-page":"Cd012836","volume":"3","author":"B Singh","year":"2019","unstructured":"Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):Cd012836.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2620_CR35","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dky096","volume":"73","author":"J Millard","year":"2018","unstructured":"Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, et al. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. J Antimicrob Chemother. 2018;73(7):1755\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2620_CR36","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126.","journal-title":"Crit Care"},{"issue":"11","key":"2620_CR37","doi-asserted-by":"publisher","first-page":"e0112624","DOI":"10.1128\/aac.01126-24","volume":"68","author":"L Hu","year":"2024","unstructured":"Hu L, Su Y, Tang X, Li Y, Feng J, He G. Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction. Antimicrob Agents Chemother. 2024;68(11):e0112624.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2620_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/FTD.0000000000000870","volume":"43","author":"K Isoda","year":"2021","unstructured":"Isoda K, Nakade J, Suga Y, Fujita A, Shimada T, Sai Y. Initial serum C-reactive protein level as a predictor of increasing serum Vancomycin concentration during treatment. Ther Drug Monit. 2021;43(5):652\u20136.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2620_CR39","doi-asserted-by":"publisher","first-page":"106750","DOI":"10.1016\/j.ijantimicag.2023.106750","volume":"61","author":"DA van den Born","year":"2023","unstructured":"van den Born DA, M\u00e4rtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, et al. Voriconazole exposure is influenced by inflammation: A population Pharmacokinetic model. Int J Antimicrob Agents. 2023;61(4):106750.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2620_CR40","doi-asserted-by":"publisher","first-page":"e0158323","DOI":"10.1128\/aac.01583-23","volume":"68","author":"A Kengo","year":"2024","unstructured":"Kengo A, Nabeemeeah F, Denti P, Sabet R, Okyere-Manu G, Abraham P, et al. Assessing potential drug-drug interactions between Clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024;68(5):e0158323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2620_CR41","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373.","journal-title":"J Infect Dis"},{"issue":"2","key":"2620_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the Pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169\u201377.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02620-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:53:08Z","timestamp":1764751988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02620-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02620-x","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Formal ethical approval was not obtained; however, all plasma drug concentration testing was performed by a certified third-party laboratory, with written informed consent for external laboratory testing obtained from each participant. The dataset used for analysis was fully anonymized prior to access and analysis. Given the retrospective design and use of de-identified data, the requirement for further institutional review and patient consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}